Press releases
- UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
- UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- UroGen Pharma Appoints David Lin as New Chief Commercial Officer
- UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
- UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
- UroGen Pharma to Participate at Upcoming Investor Conferences
- New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
More ▼
Key statistics
As of last trade Urogen Pharma Ltd (UR8:DUS) traded at 15.20, -18.72% below its 52-week high of 18.70, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.20 |
---|---|
High | 15.20 |
Low | 15.20 |
Bid | 15.20 |
Offer | 15.90 |
Previous close | 15.20 |
Average volume | 3.89 |
---|---|
Shares outstanding | 41.17m |
Free float | 37.30m |
P/E (TTM) | -- |
Market cap | 697.42m USD |
EPS (TTM) | -3.39 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 11:30 BST.
More ▼